Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

This is a strong argument for reimbursement…I think that the GLP-1R agonists, or tirzepatide, will soon enter the guidelines ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...